Is Gilead Sciences Stock a Good Investment?
Gilead Sciences Investment Advice | GILD |
- Examine Gilead Sciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Gilead Sciences' leadership team and their track record. Good management can help Gilead Sciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Gilead Sciences' business and its evolving consumer preferences.
- Compare Gilead Sciences' performance and market position to its competitors. Analyze how Gilead Sciences is positioned in terms of product offerings, innovation, and market share.
- Check if Gilead Sciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Gilead Sciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Gilead Sciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Gilead Sciences is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Gilead Sciences Stock
Researching Gilead Sciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 90.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.23. Gilead Sciences last dividend was issued on the 13th of June 2025. The entity had 2:1 split on the 28th of January 2013.
To determine if Gilead Sciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gilead Sciences' research are outlined below:
| Gilead Sciences generated a negative expected return over the last 90 days | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: If You Invested 1000 In This Stock 20 Years Ago, You Would Have This Much Today |
Gilead Sciences Quarterly Accounts Payable |
|
Gilead Sciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gilead Sciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gilead Sciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Gilead Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Gilead Sciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2000-04-27 | 2000-03-31 | -0.01 | -0.0041 | 0.0059 | 59 | ||
2000-07-27 | 2000-06-30 | -0.01 | -0.0029 | 0.0071 | 71 | ||
2002-04-30 | 2002-03-31 | -0.01 | -0.0025 | 0.0075 | 75 | ||
2005-10-18 | 2005-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2005-07-19 | 2005-06-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2004-10-21 | 2004-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2003-04-23 | 2003-03-31 | 0.02 | 0.03 | 0.01 | 50 | ||
2002-10-31 | 2002-09-30 | 0.01 | 0.02 | 0.01 | 100 |
Gilead Sciences Target Price Consensus
Gilead target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Gilead Sciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 30 | Strong Buy |
Most Gilead analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Gilead stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Gilead Sciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGilead Sciences Target Price Projection
Gilead Sciences' current and average target prices are 107.20 and 116.00, respectively. The current price of Gilead Sciences is the price at which Gilead Sciences is currently trading. On the other hand, Gilead Sciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Gilead Sciences Market Quote on 25th of June 2025
Target Price
Analyst Consensus On Gilead Sciences Target Price
Gilead Sciences Analyst Ratings
Gilead Sciences' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Gilead Sciences stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Gilead Sciences' financials, market performance, and future outlook by experienced professionals. Gilead Sciences' historical ratings below, therefore, can serve as a valuable tool for investors.Know Gilead Sciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gilead Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gilead Sciences backward and forwards among themselves. Gilead Sciences' institutional investor refers to the entity that pools money to purchase Gilead Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2025-03-31 | 18.4 M | Bank Of New York Mellon Corp | 2025-03-31 | 15.9 M | T. Rowe Price Associates, Inc. | 2025-03-31 | 14.7 M | Northern Trust Corp | 2025-03-31 | 14.4 M | Ubs Asset Mgmt Americas Inc | 2025-03-31 | 13.8 M | Jpmorgan Chase & Co | 2025-03-31 | 11.1 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 10.5 M | Legal & General Group Plc | 2025-03-31 | 10.3 M | Amvescap Plc. | 2025-03-31 | 10.1 M | Vanguard Group Inc | 2025-03-31 | 117.5 M | Blackrock Inc | 2025-03-31 | 116.1 M |
Gilead Sciences' market capitalization trends
The company currently falls under 'Mega-Cap' category with a current market capitalization of 132.09 B.Market Cap |
|
Gilead Sciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.02 | 0.01 | |
| Return On Capital Employed | 0.04 | 0.03 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Determining Gilead Sciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Gilead Sciences is a good buy. For example, gross profit margin measures Gilead Sciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gilead Sciences' profitability and make more informed investment decisions.
Gilead Sciences' Earnings Breakdown by Geography
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.
Evaluate Gilead Sciences' management efficiency
Gilead Sciences has return on total asset (ROA) of 0.1214 % which means that it generated a profit of $0.1214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3265 %, meaning that it created $0.3265 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of June 25, 2025, Return On Tangible Assets is expected to decline to 0.01. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 6.5 B, whereas Other Assets are forecasted to decline to about 1.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 15.43 | 16.21 | |
| Tangible Book Value Per Share | (7.23) | (6.87) | |
| Enterprise Value Over EBITDA | 29.75 | 31.24 | |
| Price Book Value Ratio | 5.96 | 7.85 | |
| Enterprise Value Multiple | 29.75 | 31.24 | |
| Price Fair Value | 5.96 | 7.85 | |
| Enterprise Value | 107.4 B | 112.8 B |
The decision-making processes within Gilead Sciences are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Basic technical analysis of Gilead Stock
As of the 25th of June, Gilead Sciences retains the Downside Deviation of 2.08, risk adjusted performance of 0.0424, and Market Risk Adjusted Performance of 0.0786. Gilead Sciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Gilead Sciences treynor ratio, and the relationship between the variance and potential upside to decide if Gilead Sciences is priced fairly, providing market reflects its last-minute price of 107.2 per share. Given that Gilead Sciences has jensen alpha of 0.0147, we strongly advise you to confirm Gilead Sciences's regular market performance to make sure the company can sustain itself at a future point.Gilead Sciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gilead Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Deborah Telman over three months ago Disposition of 187 shares by Deborah Telman of Gilead Sciences at 93.07 subject to Rule 16b-3 | ||
Andrew Dickinson over six months ago Disposition of 3025 shares by Andrew Dickinson of Gilead Sciences subject to Rule 16b-3 | ||
Sandra Patterson over six months ago Disposition of 748 shares by Sandra Patterson of Gilead Sciences subject to Rule 16b-3 | ||
Johanna Mercier over a year ago Acquisition by Johanna Mercier of 20086 shares of Gilead Sciences subject to Rule 16b-3 | ||
Kevin Young over a year ago Acquisition by Kevin Young of 26000 shares of Gilead Sciences subject to Rule 16b-3 |
Gilead Sciences' Outstanding Corporate Bonds
Gilead Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gilead Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gilead bonds can be classified according to their maturity, which is the date when Gilead Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| GILEAD SCIENCES INC Corp BondUS375558AX11 | View | |
| GILEAD SCIENCES INC Corp BondUS375558AS26 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BK80 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BJ18 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BM47 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BA09 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BG78 | View | |
| GILEAD SCIENCES INC Corp BondUS375558BF95 | View |
Understand Gilead Sciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Gilead Sciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0424 | |||
| Market Risk Adjusted Performance | 0.0786 | |||
| Mean Deviation | 1.58 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 2.08 | |||
| Coefficient Of Variation | 4074.3 | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.22 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0147 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0686 | |||
| Maximum Drawdown | 10.13 | |||
| Value At Risk | (3.09) | |||
| Potential Upside | 2.78 | |||
| Downside Variance | 4.33 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (1.63) | |||
| Skewness | 0.2205 | |||
| Kurtosis | 1.34 |
| Risk Adjusted Performance | 0.0424 | |||
| Market Risk Adjusted Performance | 0.0786 | |||
| Mean Deviation | 1.58 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 2.08 | |||
| Coefficient Of Variation | 4074.3 | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.22 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0147 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0686 | |||
| Maximum Drawdown | 10.13 | |||
| Value At Risk | (3.09) | |||
| Potential Upside | 2.78 | |||
| Downside Variance | 4.33 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (1.63) | |||
| Skewness | 0.2205 | |||
| Kurtosis | 1.34 |
Consider Gilead Sciences' intraday indicators
Gilead Sciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gilead Sciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Gilead Sciences Corporate Filings
F4 | 17th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of May 2025 Other Reports | ViewVerify | |
8K | 8th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Gilead Stock media impact
There is far too much social signal, news, headlines, and media speculation about Gilead Sciences that are available to investors today. This information is accessible both publicly - through Gilead Sciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Gilead-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Gilead Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gilead Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gilead Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gilead Sciences alpha.
Gilead Sciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Gilead Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Gilead Sciences Historical Investor Sentiment
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Gilead Sciences.
Gilead Sciences Maximum Pain Price Across September 19th 2025 Option Contracts
Gilead Sciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Gilead Sciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Gilead Sciences' options.
Gilead Sciences Corporate Management
| Mr MD | VP Development | Profile | |
| SeeChun MD | VP Oncology | Profile | |
| Monica Tijerina | Clinical Manufacturing | Profile | |
| Janet Dorling | Senior Solutions | Profile | |
| Johanna Mercier | Chief Commercial Officer | Profile | |
| Bilal Piperdi | Vice Oncology | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.248 | Dividend Share 3.1 | Earnings Share 4.76 | Revenue Per Share | Quarterly Revenue Growth (0) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Gilead Sciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.